WGS · GeneDx Holdings Corp. · Stock research

Current Thesis

The binary that had defined this name since the May 5 crash resolved on August 3, and it resolved in the bulls' favour. Blended average reimbursement rate (ARR) — the metric that took the stock down 49% in a day — printed roughly $3,250, about flat sequentially against the ~$3,300 Q1 baseline. Exome/genome volume set a record at 30,785 tests, +32% YoY. Revenue of $114.44M beat the $111.01M consensus, adjusted net income turned positive at $0.4M a quarter ahead of guidance, and FY26 revenue guidance was affirmed at $475–490M with FY26 E/G volume growth raised to "at least 30%" from the "at least 20%" set at the May 4 cut. Price followed: $63.25 on July 23 to $78.08 on August 14, through the $67.51 July 2 recovery high and through the $74.83 200-day level as it stood in late July. The leg on offer is the repair trade — pricing stopped deteriorating and operating leverage arrived early. What that leg now costs is a 91.6% three-month advance carrying an RSI(14) of 74.0, with no company-scheduled event before the Q3 print.

Bullish and bearish views on GeneDx Holdings Corp.

The model's bull view on GeneDx Holdings Corp. (WGS), in brief: Q2 2026 (reported 2026-08-03): total revenue $114.44M vs $111.01M consensus; exome/genome revenue $100.3M, +17% YoY. The bear view: The FY26 range was affirmed, not raised — $475–490M is unchanged from the May 4 cut and sat against a $478.4M consensus. Both cases follow in full.

Bull Case

• Q2 2026 (reported 2026-08-03): total revenue $114.44M vs $111.01M consensus; exome/genome revenue $100.3M, +17% YoY.
• Blended ARR ~$3,250, roughly flat QoQ. Genome fell to 32% of insurance-based outpatient volume from close to 40% in Q1 — genome ARR runs about half of exome, so the mix drag that caused the May guide cut eased.
• Record 30,785 E/G tests, +32% YoY; FY26 E/G volume growth guidance raised to at least 30%, with E/G revenue growth guided at least 20%.
• Adjusted net income $0.4M — profitability one quarter earlier than management had guided. Adjusted gross margin 70%, up from 69% in Q1 2026.
• Q3 2026 guidance issued: revenue $122–124M, E/G revenue $110–112M, 33,200 tests, adjusted net income ~$2M.
• Funding: cash, equivalents, marketable and restricted securities of $133.5M at June 30, 2026; on August 3 the Blackstone facility was amended with an additional $50.0M term loan (aggregate $150.0M) and a Blackstone affiliate bought ~$5.0M of Class A stock at $61.00 in a private placement, taking pro forma cash to roughly $188M.
• Sell-side moved with the print: Canaccord Genuity raised its target to $90 from $75 (2026-08-03, Buy); BTIG reiterated Buy with a $90 target (2026-08-04).
• GUARDIAN newborn screening now past 22,000 newborns sequenced, with actionable conditions found in 3.2% and a 75% parental opt-in rate (Q2 2026 slides).

Bear Case

• The FY26 range was affirmed, not raised — $475–490M is unchanged from the May 4 cut and sat against a $478.4M consensus. The Q3 revenue guide of $122–124M was reported as below the Street's quarterly figure.
• ARR near $3,250 is stabilisation at a lower plateau; the 2025 level was $3,750. FY26 guides volume growth of at least 30% but E/G revenue growth of at least 20%; the wedge between those two lines is price realisation that has not come back.
• Leverage stepped up on the same day as the beat: $150.0M first-lien term debt at Term SOFR + 4.50% with a 1.50% floor, secured on substantially all assets, five-year maturity from the original February 27, 2026 agreement that refinanced the Perceptive 2023 facility. That sits against a company that just produced $0.4M of adjusted net income in a quarter.
• The last negotiated equity mark is $61.00 (Blackstone affiliate private placement, 2026-08-03) versus the $78.08 close on 2026-08-14.
• The Hagens Berman securities class action (class period April 16, 2025 – May 4, 2026) remains pending; the August 3 lead-plaintiff deadline has passed and the matter now proceeds on the court's schedule.
• Shares remain 53.4% below the $167.51 52-week high, and the $31.2M Fabric Genomics impairment — about 94% of the $33.2M cost, written off inside roughly a year — is still in the capital-allocation record.
• Adjusted profitability is not GAAP profitability: the Q2 8-K coverage described a continuing GAAP loss. The first wire print of adjusted EPS at $(0.28) was corrected to $0.01, so screens that cached the miss may still show it.

Setup & Price Structure

• Reference close $78.08 (2026-08-14). RSI(14) 74.0. Three-month return +91.6%. Distance from the $167.51 52-week high: −53.4%.
• Path since the crash: $32.21 (May low) → $59.92 (June 12) → $67.51 (July 2) → $63.25 (July 23) → $78.08 (August 14). The August 3 print carried price through both the July recovery high and the $74.83 200-day reading measured in late July, which is the structural change since the last update — the recovery is no longer capped below the long moving average.
• The shelf created by that move runs roughly $67.51 to $74.83. Losing it puts the August 3 gap behind the market and re-exposes the $59.92–$63.25 congestion.
• The narrative is accelerating, dated by the August 3 beat-and-affirm, the August 3–4 target raises to $90 at Canaccord and BTIG, and the move to $78.08 by August 14. It is an early-stage repair leg, not a fresh secular story — the name is still barely half its 52-week high.
• Crowding and positioning observables, stated without a verdict: RSI(14) at 74.0; a 91.6% three-month move; published targets clustered at $90 against a $78.08 close, so the visible sell-side headroom is thin; $5.0M of stock issued to a Blackstone affiliate at $61.00 on the day of the print; no earnings date inside the next 30 days to force a repricing either way.

Catalyst Calendar (next 30 days)

• 2026-08-16 → 2026-09-15: no confirmed company event. The Q2 2026 slide deck disclosed no upcoming conference dates, and no earnings, regulatory or product date has been set inside the window.
• ~2026-11-02 (est.): Q3 2026 print. Q2 landed 2026-08-03; this is the next scheduled test of blended ARR, the $122–124M revenue guide and the 33,200-test volume guide.
• ~2026-09-30 (est., court's discretion): appointment of lead plaintiff and consolidation in the securities class action following the elapsed August 3 deadline. Timing is not fixed by statute in practice and may slip.

What Would Change Our Mind

The whole leg is the August 3 gap. If that gap fills, the print stops being evidence of a regime change and becomes a one-quarter bounce inside a busted-growth tape. Concretely: a weekly close below $67 surrenders the $67.51 July 2 recovery high and the post-print shelf, reopening the $59.92–$63.25 zone. On fundamentals, a Q3 report showing blended ARR under roughly $3,150, or revenue below the $122M low end of the company's own guide, would show pricing never stabilised and would return the name to the May 5 regime. A second FY26 guidance cut would do the same faster. On the other side of the ledger, the theme flipping to saturated — coverage clustering at the $90 target band with price already into it and no dated event before November — would mean the easy part of the repricing has been paid for, even if nothing breaks.

Correlation Notes

• Moves with the clinical-diagnostics reimbursement complex: ILMN (sequencing consumables and GUARDIAN partner), NTRA, EXAS, MYGN, FLGT. CMS/MolDX and commercial-payer coverage headlines hit the group together, and WGS's specific sensitivity is outpatient genome coverage.
• Rate-sensitive through the capital structure rather than the customer: the $150.0M first-lien facility floats at Term SOFR + 4.50% with a 1.50% floor, so front-end rate moves feed directly into interest expense for a business at roughly breakeven on an adjusted basis.
• Correlation to broad biotech risk appetite (XBI) exists but is second-order here — the two gaps that set the year, May 5 and August 3, were both idiosyncratic ARR prints.